U
ROSG

UBS’s Rosetta Genomics Ltd. ROSG Stock Holding History

UBS’s Portfolio ROSG Stock Details ROSG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$4K Buy
83
+58
+232% +$2.64K ﹤0.01% 9705
2014
Q2 		$1K Sell
25
-83
-77% -$4.11K ﹤0.01% 10297
2014
Q1 		$6K Buy
+108
New +$5.58K ﹤0.01% 9436

Other funds holding ROSG

Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
HCM
Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS's ROSG Position: Q3 2014 in Review

UBS reduced its Rosetta Genomics Ltd. (ROSG) stake by 37% in Q3 2014, selling an estimated $8.27K and leaving 313 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #8577.

UBS first reported a position in ROSG in Q3 2013 and has held it in 4 quarters since. The position peaked at $26K in Q2 2014. 14 funds tracked by Wall St. Rank hold ROSG as of Q3 2014.

  • UBS held 313 shares of Rosetta Genomics Ltd. worth $13K as of Q3 2014.
  • UBS sold 182 Rosetta Genomics Ltd. shares in Q3 2014, an estimated $8.27K.
  • Rosetta Genomics Ltd. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8577 holding.
  • UBS first reported a position in Rosetta Genomics Ltd. in Q3 2013 and has held it in 4 quarters since.
  • UBS's Rosetta Genomics Ltd. position peaked at $26K in Q2 2014.
  • 14 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.